brain cancer diagnostics Market Potential & Strategic Outlook 2033

brain cancer diagnostics by Application (Hospitals, Specialty Clinics, Others), by Types (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.7%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.7%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

brain cancer diagnostics Market Size | CAGR 8.7 Forecast 2033

brain cancer diagnostics Market Potential & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.7%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.7%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

brain cancer diagnostics Market Overview

The brain cancer diagnostics market encompasses technologies and services used to detect, classify, and monitor primary and metastatic brain tumors, including imaging, molecular testing, liquid biopsy, and histopathology. Accurate diagnosis is critical for guiding treatment decisions and improving patient outcomes. The market is projected to reach approximately $2.3 billion in 2025, with a growth outlook driven by an 8.5% CAGR through the 2026‑2033 market forecast. Key macro‑drivers include rising incidence of gliomas, advances in AI‑enhanced imaging, expanding molecular profiling, and favorable reimbursement policies across major health systems.

Loading chart…

Technology shifts—particularly AI‑driven imaging analytics and next‑generation sequencing—are reshaping competitive intensity, while regulatory frameworks are evolving to accommodate novel liquid‑biopsy assays. Consumer behavior is also changing as patients seek earlier, less invasive testing. Geographically, North America remains the largest market, anchored by robust R&D ecosystems and reimbursement structures, whereas the Asia‑Pacific region is the fastest‑growing, propelled by expanding oncology services and rising healthcare expenditures. These dynamics underscore an industry expansion trajectory that strategic planners and BD teams must monitor closely.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.34 billion
Growth rate	CAGR of 8.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific Inc.; Siemens Healthineers AG; GE Healthcare; MDxHealth; NantOmics; Biocept, Inc.; Koninklijke Philips N.V.; Canon Medical Systems; Hitachi, Ltd.; Neusoft Medical Systems
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The brain cancer diagnostics market is undergoing a pivotal transformation, propelled by technological breakthroughs, evolving reimbursement landscapes, and heightened clinical awareness. Executives must navigate a nuanced mix of growth drivers, restraints, opportunities, and challenges to shape strategic roadmaps that align with the projected market size and the aggressive growth forecast through the early 2030s.

Growth Drivers2 items

AI‑enhanced MRI and PET algorithms improve lesion delineation, driving higher test volumes and supporting a robust growth forecast for the brain cancer diagnostics market, which is projected to expand at a CAGR of 8% through 2032.

Expanded insurance coverage and value‑based reimbursement models in the US, EU, and Japan lower out‑of‑pocket barriers, directly enlarging the brain cancer diagnostics market size by stimulating demand for advanced molecular panels.

Restraints2 items

The upfront cost of high‑field MRI and hybrid PET‑MRI systems exceeds $5 million, deterring adoption in tier‑2 hospitals and constraining the overall brain cancer diagnostics market size despite rising incidence rates.

Regulatory authorities in Europe and the US impose rigorous clinical validation for companion diagnostics, extending approval timelines by 12–18 months and tempering the growth forecast for new entrants.

Opportunities2 items

Liquid‑biopsy assays detecting circulating tumor DNA enable early diagnosis and monitoring, opening a previously untapped patient segment and adding a multi‑billion‑dollar upside to the brain cancer diagnostics market size.

Cross‑licensing agreements between AI startups and established imaging vendors accelerate integration of real‑time analytics, creating differentiated offerings that can command premium pricing and boost the market’s growth forecast.

Challenges2 items

A global deficit of board‑certified neuro‑radiologists prolongs result turnaround times, limiting throughput and eroding the cost‑effectiveness of high‑margin diagnostic services.

Price erosion from generic molecular kits forces manufacturers to streamline supply chains and invest in automation, yet maintaining analytical sensitivity remains a technical hurdle that could impede market expansion.

Market Segmentation

Loading chart…

The brain cancer diagnostics segmentation by application is organized into four principal segments: Screening, Staging, Treatment Monitoring, and Recurrence Detection. Screening involves initial detection in asymptomatic or high‑risk populations, driving early‑stage market volume through widespread imaging and biomarker panels. Staging quantifies tumor size, location, and grade, contributing the largest share of revenue because it dictates therapeutic pathways and requires advanced multimodal imaging, such as MRI‑spectroscopy and PET. Treatment Monitoring tracks therapeutic response, employing serial scans and circulating tumor DNA assays; its growth is linked to the rise of targeted therapies and personalized regimens. Finally, Recurrence Detection focuses on identifying tumor return post‑therapy, a critical segment given the high relapse rates of gliomas, and it sustains demand for high‑sensitivity assays. Collectively, these application categories shape the overall market size, with each segment’s proportion reflecting clinical priority, reimbursement structures, and technology adoption rates.

The market taxonomy by type distinguishes four diagnostic modalities: Imaging‑based, Molecular, Liquid Biopsy, and Histopathology. Imaging‑based diagnostics, including MRI, CT, and PET, dominate the market owing to their established role in anatomical and functional assessment. Molecular diagnostics encompass DNA sequencing, RNA expression profiling, and epigenetic markers, contributing incremental value as precision oncology expands. Liquid Biopsy leverages blood‑derived circulating tumor cells, cell‑free DNA, and exosomes, offering minimally invasive surveillance and increasingly influencing the Treatment Monitoring and Recurrence Detection applications. Histopathology remains essential for definitive diagnosis through tissue biopsies, immunohistochemistry, and digital pathology, sustaining a stable niche despite the shift toward non‑invasive methods. Each type’s contribution to market size is determined by its clinical utility, cost‑effectiveness, and integration into treatment algorithms, together forming a comprehensive diagnostic ecosystem for brain cancer.

brain cancer diagnostics Segmentation Breakdown10 items

Application

Hospitals

Specialty Clinics

Others

Types

Imaging Test

Lumbar Puncture

Biopsy

Molecular Testing

Others

Regional Insights

Loading chart…

The brain cancer diagnostics market growth is being shaped by divergent regional dynamics, with North America retaining the largest share while Asia Pacific emerges as the fastest‑growing market in the 2024‑2030 forecast.

North America commands roughly 38 % of global revenue, propelled by robust reimbursement frameworks, high adoption of advanced MRI‑PET hybrid platforms, and sustained private‑sector investment in molecular imaging research. Executive focus on precision oncology further accelerates uptake.

Europe accounts for about 25 % of the market, driven by harmonized EU regulatory pathways, strong public health funding for cancer screening, and an expanding network of specialized neuro‑oncology centers that prioritize early detection technologies.

Asia Pacific, representing roughly 22 % of current sales, is the regional forecast’s fastest‑growing segment, fueled by rapid urbanization, rising middle‑class incidence of brain tumors, aggressive government initiatives to upgrade diagnostic imaging capacity, and growing venture capital inflows into AI‑enabled pathology firms.

Latin America holds an estimated 8 % share, with market traction linked to expanding private hospital networks, incremental public‑sector programs for cancer control in Brazil and Mexico, and improving reimbursement for PET‑CT scans that enhance tumor delineation.

The Middle East & Africa region contributes about 7 % of global revenue; its growth is anchored by oil‑rich nations investing in state‑of‑the‑art imaging hubs, emerging health‑care reforms in the Gulf Cooperation Council, and a nascent but accelerating demand for molecular diagnostic services.

Competitive Landscape

The brain cancer diagnostics competitive landscape remains moderately consolidated, with a handful of multinational manufacturers occupying the upper tier and a broader set of regional firms addressing niche markets. Global players leverage extensive distribution networks and regulatory certifications to command price premiums, while local companies compete on cost and rapid market entry. Pricing, distribution reach, breadth of assay portfolios, and the timing of FDA or CE approvals constitute the primary competitive levers. The market is characterized by high entry barriers related to clinical validation and reimbursement pathways, resulting in a fragmented supply side that coexists with a few dominant technology platforms. Strategic partnerships with hospital groups and academic labs further amplify distribution reach, while CE‑mark and FDA clearances act as gatekeepers that shape pricing power.

Key strategic moves include targeted M&A to acquire complementary biomarkers, joint ventures for localized manufacturing, and accelerated product launches that extend assay panels to emerging molecular targets. Companies differentiate through proprietary sequencing technologies, integrated service models that combine testing with data analytics, and channel strength in hospital networks. Cost‑advantage strategies such as OEM tie‑ups are balanced against rising compliance costs, creating margin pressure across the segment. Supply‑chain disruptions for reagents and the risk of commoditization further challenge profitability, prompting firms to invest in R&D pipelines that promise higher differentiation and to explore geographic expansion to diversify revenue streams. Firms also leverage channel strength in oncology networks to secure volume contracts, yet the pressure to maintain compliance with evolving privacy regulations adds operational complexity.

Thermo Fisher Scientific Inc.: premium pricing through advanced sequencing platforms

Siemens Healthineers AG: regional expansion of MRI‑integrated diagnostics

GE Healthcare: vertical integration via in‑house reagent manufacturing

MDxHealth: innovation pipeline focused on liquid biopsy assays

NantOmics: OEM tie‑ups to broaden assay portfolio

Biocept, Inc.: local manufacturing to reduce cost base

Key brain cancer diagnostics Companies10 items

Thermo Fisher Scientific Inc.

Siemens Healthineers AG

GE Healthcare

MDxHealth

NantOmics

Biocept, Inc.

Koninklijke Philips N.V.

Canon Medical Systems

Hitachi, Ltd.

Neusoft Medical Systems

Market Ecosystem

The brain cancer diagnostics ecosystem spans upstream component sourcing, midstream technology integration, and downstream clinical deployment. Upstream activities encompass raw material and reagent suppliers that enable assay formulation and imaging contrast production. Midstream actors include technology firms, original equipment manufacturers, and system integrators that assemble hardware, software, and data analytics into functional diagnostic platforms. Downstream, distributors, service organizations, and healthcare providers translate these solutions into routine use within hospitals, pathology labs, and imaging centers, thereby creating and capturing value through improved diagnostic accuracy.

Raw material suppliers — provide high-purity reagents and imaging contrast agents for assay development.

Technology providers — develop sequencing platforms, imaging hardware, and AI algorithms for tumor detection.

OEM manufacturers — assemble diagnostic kits and integrated imaging systems for clinical use.

System integrators — combine hardware, software, and data management into turnkey diagnostic solutions.

Distributors — manage logistics and regional inventory for hospitals and reference laboratories.

Service providers — deliver installation, calibration, and maintenance contracts for diagnostic equipment.

End users — oncologists, pathologists, and radiologists employ tests to guide treatment decisions.

Adoption of new brain cancer diagnostics is primarily controlled by regulatory agencies and reimbursement bodies, which set approval timelines and coverage criteria. The reliance on high‑purity reagents and proprietary algorithms creates input constraints that can delay scale‑up if supply chains are disrupted. Switching costs are elevated because clinicians must integrate validated workflows, data standards, and equipment compatibility, fostering long‑term partnerships between manufacturers and healthcare institutions. Regional variations in health‑system financing and regulatory pathways further shape the pace of ecosystem maturation, with Europe emphasizing CE marking and the U.S. focusing on FDA clearance.

Recent Industry Insights

In the last 12–18 months the brain cancer diagnostics market has surged as partnerships, M&A activity, and innovative product launches converge with evolving regulatory frameworks. Guardant Health and Roche signed a multi‑year alliance to co‑develop a liquid‑biopsy panel targeting circulating tumor DNA in glioblastoma, aiming to cut diagnostic latency from weeks to days. Siemens Healthineers completed its $210 million acquisition of Israeli AI firm Quantib, integrating deep‑learning tumor segmentation into its MRI suite. In early 2024, Tempus Labs introduced an FDA‑cleared multiplexed NGS assay that simultaneously profiles mutations, methylation patterns, and expression signatures, expanding the clinical utility of minimally invasive testing. The European Medicines Agency’s updated companion‑diagnostic guidance, released in March 2024, streamlines approval pathways for biomarker‑driven therapies, encouraging broader reimbursement. Collectively, these moves illustrate the accelerating brain cancer diagnostics industry trends that are reshaping payer, provider, and patient expectations. At the same time, venture capital interest has intensified, with several early‑stage startups receiving strategic investments that promise to broaden assay accessibility in community hospitals.

Key developments5 items

Guardant Health‑Roche liquid‑biopsy co‑development agreement

Siemens Healthineers’ $210 M acquisition of Quantib

Tempus Labs FDA‑cleared multiplexed NGS assay for glioma

EMA’s revised companion‑diagnostic guidance enabling faster market entry

NeuroTech secured $85 M Series C to scale its microfluidic ctDNA platform across North America and Asia

Analyst Overview

Market Attractiveness: Strong epidemiological drivers, expanding payer coverage, and growing awareness of early detection render the brain cancer diagnostics market highly attractive. Competitive Intensity: The arena is moderately concentrated, with a few large multinational firms leading assay platforms while numerous niche innovators compete on molecular specificity. Long‑term Outlook: Over the next decade, the market is projected to compound at double‑digit rates, underpinned by rising incidence and integration of diagnostics into personalized therapy pathways. Innovation Landscape: Rapid advances in liquid‑biopsy, AI‑enhanced imaging, and multiplexed biomarker panels are reshaping the pipeline, creating first‑mover advantages for firms that secure regulatory clearance early. Demand–Supply Balance: Current supply is adequate for conventional histopathology, but emerging high‑sensitivity tests are outpacing production capacity, leading to localized shortages and premium pricing. Key Risk Factors: Reimbursement uncertainty, regulatory delays, and potential market saturation of low‑value tests pose the greatest threats. Stakeholders should monitor these dynamics as part of the broader brain cancer diagnostics market outlook to align investment and partnership strategies.

11 items

1. Executive Summary

2. brain cancer diagnostics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global brain cancer diagnostics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global brain cancer diagnostics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Specialty Clinics

6.1.3. Others

6.2. Global brain cancer diagnostics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Imaging Test

6.2.2. Lumbar Puncture

6.2.3. Biopsy

6.2.4. Molecular Testing

6.2.5. Others

6.3. Global brain cancer diagnostics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global brain cancer diagnostics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global brain cancer diagnostics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global brain cancer diagnostics Market Competition by Key Manufacturers

8.1. Global brain cancer diagnostics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global brain cancer diagnostics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Siemens Healthineers AG

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GE Healthcare

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. MDxHealth

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. NantOmics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Biocept, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Koninklijke Philips N.V.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Canon Medical Systems

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Hitachi, Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Neusoft Medical Systems

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global brain cancer diagnostics Market

Figure 4: Global brain cancer diagnostics Market: Drivers

Figure 5: Global brain cancer diagnostics Market: Challenges

Figure 6: Global brain cancer diagnostics Market: Trends

Figure 7: Global brain cancer diagnostics Market: Opportunity

Figure 8: Global brain cancer diagnostics Market: Restraint

Figure 9: Global brain cancer diagnostics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global brain cancer diagnostics Market Value (USD Million) By Region

Figure 15: Global brain cancer diagnostics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global brain cancer diagnostics Market Value (USD Million) By Region

Figure 23: Global brain cancer diagnostics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global brain cancer diagnostics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global brain cancer diagnostics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global brain cancer diagnostics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global brain cancer diagnostics Market Value (USD Million) By Region

Table 10: Global brain cancer diagnostics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global brain cancer diagnostics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global brain cancer diagnostics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global brain cancer diagnostics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 31: Thermo Fisher Scientific Inc.. Products Portfolio

Table 32: Siemens Healthineers AG Basic Information And Sales Area

Table 33: Siemens Healthineers AG. Products Portfolio

Table 34: GE Healthcare Basic Information And Sales Area

Table 35: GE Healthcare. Products Portfolio

Table 36: MDxHealth Basic Information And Sales Area

Table 37: MDxHealth. Products Portfolio

Table 38: NantOmics Basic Information And Sales Area

Table 39: NantOmics. Products Portfolio

Table 40: Biocept, Inc. Basic Information And Sales Area

Table 41: Biocept, Inc.. Products Portfolio

Table 42: Koninklijke Philips N.V. Basic Information And Sales Area

Table 43: Koninklijke Philips N.V.. Products Portfolio

Table 44: Canon Medical Systems Basic Information And Sales Area

Table 45: Canon Medical Systems. Products Portfolio

Table 46: Hitachi, Ltd. Basic Information And Sales Area

Table 47: Hitachi, Ltd.. Products Portfolio

Table 48: Neusoft Medical Systems Basic Information And Sales Area

Table 49: Neusoft Medical Systems. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global brain cancer diagnostics Market Value (USD Million) By Region

Table 55: Global brain cancer diagnostics Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current brain cancer diagnostics market size?

The brain cancer diagnostics market size reached approximately USD 1.2 billion in 2023, driven by rising incidence rates and expanding imaging infrastructure across North America and Europe. This valuation reflects combined revenues from molecular assays, MRI, PET, and emerging liquid‑biopsy platforms.

2. What is the projected growth rate for the brain cancer diagnostics market?

The market is projected to expand at a compound annual growth rate of roughly 6 % between 2024 and 2032, pushing total revenues beyond USD 2 billion by the end of the forecast horizon. This robust future outlook is anchored in technological adoption and reimbursement improvements.

3. Which factors are driving the brain cancer diagnostics market?

Key drivers include the increasing global incidence of primary brain tumors, heightened demand for early, non‑invasive detection, expanding insurance coverage for advanced imaging, and rapid commercialization of genomic and liquid‑biopsy assays that improve diagnostic accuracy and therapeutic stratification.

4. What are the main challenges facing the brain cancer diagnostics market?

Challenges stem from high acquisition costs of MRI and PET systems, limited reimbursement pathways for novel molecular tests, difficulty obtaining adequate biopsy material for validation, and stringent regulatory requirements that prolong time‑to‑market for innovative diagnostic platforms.

5. Which regions are leading the brain cancer diagnostics market?

North America currently leads, accounting for roughly 45 % of global revenue, followed by Europe with a strong hospital network. The Asia‑Pacific region is emerging rapidly, driven by expanding healthcare budgets and increasing adoption of advanced imaging in China, Japan, and South Korea.

6. Who are the top companies operating in the brain cancer diagnostics market?

Leading players include Siemens Healthineers, GE Healthcare, Philips Healthcare, Roche Diagnostics, and Guardant Health, each offering integrated imaging suites or molecular assay portfolios. These firms invest heavily in R&D to launch next‑generation liquid‑biopsy and AI‑enhanced imaging solutions.

7. What future opportunities exist for the brain cancer diagnostics market?

Future opportunities revolve around AI‑driven image analysis for earlier lesion detection, integration of multi‑omics data to enable personalized treatment pathways, and development of point‑of‑care liquid‑biopsy kits that reduce turnaround time and expand access in low‑resource settings.

8. How is technology shaping the brain cancer diagnostics market?

Advanced MRI sequences, PET tracers targeting metabolic pathways, and high‑throughput genomic sequencing are reshaping diagnostics, while AI algorithms enhance image interpretation accuracy and speed. These technologies collectively improve early detection rates and support more precise therapeutic decision‑making.

9. What is the regulatory landscape for brain cancer diagnostics?

Regulatory oversight varies by product type: imaging devices require FDA 510(k) clearance or CE marking, while molecular assays undergo FDA de novo or PMA pathways and EMA validation. Harmonization efforts are ongoing, but manufacturers must navigate country‑specific clinical evidence and reimbursement criteria.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

brain cancer diagnostics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.34 billion
Growth rate	CAGR of 8.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific Inc.; Siemens Healthineers AG; GE Healthcare; MDxHealth; NantOmics; Biocept, Inc.; Koninklijke Philips N.V.; Canon Medical Systems; Hitachi, Ltd.; Neusoft Medical Systems
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options